Germany-based Camelot Consulting Group has announced that it has developed a blockchain solution for sensitive medical data management, CoinTelegraph reported.

The company said that innovative cell therapies, a promising form of cancer treatment, involve highly complex procedures and the exchange of sensitive patient data between many actors. To address this problem, Camelot developed Hypertrust X-Chain – a blockchain-based solution that ensures the highest level of security in the storage and exchange of patient data.

"Since highly innovative out-of-body cell therapies are often the last hope for many patients, nothing should go wrong in the overall process. That's why we've come up with a digital application that not only ensures maximum data-sharing and data-storage security, but also puts the patient at the center," Josef Packowski, CEO of CAMELOT Consulting Group, said (loosely translated).

The company explained that in the case of extracorporeal cell therapies, cells are removed from the patient, then taken to the pharmaceutical manufacturer in frozen form, processed there in an elaborate, multi-stage process, sent back frozen and then reintroduced to the patient on site. The process involves a number of entities including the treating clinic, the cell collection center, logistics service providers and pharmaceutical companies.

Using blockchain technology, Camelot said that relevant patient data is made available to the actors authorized for the therapy process by means of a decentralized data storage.

“All data transactions take place exclusively between verified participants and are stored unchangeably and consistently through the encrypted storage in the blockchain,” it said, adding that Hypertrust X-Chain “enables flexible integration of partner systems, real-time temperature, location and quality control as well as secure guarantees of origin.”